Soha Ibrahim
Family · Dearborn Heights, MINPI 1083274542
Payments from drug & device makers
Across 278 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$711
- GSK$567
- AstraZeneca$521
- Ironwood Pharmaceuticals, Inc$404
- Pfizer$300
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$296
- plus $3K from 37 others
What the payments were for
- Food & beverage$5,382100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$375
- JARDIANCE$249
- FARXIGA$130
- AIRSUPRA$125
How this compares
$5,382 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 206 | $134,616 |
| LinzessLinaclotide | 74 | $43,927 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $41,101 |
| FarxigaDapagliflozin Propanediol | 65 | $39,638 |
| JanuviaSitagliptin Phosphate | 56 | $33,662 |
| EliquisApixaban | 46 | $31,201 |
| ProliaDenosumab | 15 | $24,685 |
| TrulicityDulaglutide | 24 | $23,609 |
| OzempicSemaglutide | 23 | $22,559 |
| TradjentaLinagliptin | 28 | $19,367 |
| MyrbetriqMirabegron | 41 | $18,813 |
| MounjaroTirzepatide | 16 | $16,726 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 66 | $11,899 |
| Diclofenac Sodium | 167 | $11,818 |
| BrilintaTicagrelor | 23 | $10,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $290 | $153,983234 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $567 | $61,012114 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $521 | $52,83699 claims |
| MerckJanuvia, Janumet | $152 | $44,26674 claims |
| AbbVieLinzess | $274 | $43,92774 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $711 | $40,33440 claims |
| PfizerEliquis | $300 | $31,20146 claims |
| AmgenProlia | $161 | $24,68515 claims |
| Novo NordiskOzempic | $151 | $22,55923 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $24 | $11,89966 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $296 | $7,30113 claims |
| NovartisEntresto | $89 | $6,73111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Dearborn Heights
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.